# Diagnostic Value of Endoscopic Narrow-Band Imaging Technique in Early Gastric Cancer and Precancerous Lesions.

> **Reliability concern:** This paper was retracted on 2023-10-18. See notice: 10.1155/2023/9894170.

- **DOI:** [10.1155/2022/9205150](https://doi.org/10.1155/2022/9205150)
- **Rating:** Limited (2.1 out of 5)
- **Verdict:** Assesses NBI plus magnification for early gastric lesion diagnosis, but pervasive internal count contradictions and disease-term substitution make the reported accuracy metrics unreliable.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-01
- **Evaluation page:** https://www.nabu.science/paper/10.1155%2F2022%2F9205150

## Strengths

- **Histopathology reference standard stated** The study explicitly defines histopathology as the “gold standard” for diagnosis, which is the appropriate anchor for evaluating endoscopic diagnostic performance.
  - Dimension: methodological rigour
  - Location: Methods §2.2
- **Operational diagnostic criterion described** Use of the VS classification criteria (demarcation line with irregular microsurface or microvascular pattern) provides a recognizable rule for classifying lesions during NBI assessment.
  - Dimension: methodological rigour
  - Location: Methods §2.2–§2.3
- **Clinically relevant detection problem** The manuscript targets early gastric cancer and precancerous lesion detection during endoscopy, a well-recognized clinical need described in the Introduction and Discussion.
  - Dimension: application pathway
  - Location: Introduction §1; Discussion §4

## Limitations

- **Contradictory core case counts** Pathology distributions for Group A differ between the Abstract and Results §3.2, and Group A numbers appear inside the Group B subsection (§3.3), undermining confidence in the reported accuracy calculations.
  - Dimension: reporting
  - Location: Abstract; Results §3.2–§3.3
- **Systematic disease-term substitution** Multiple sections refer to “leukemia” in contexts where gastric cancer is intended, including Results and Discussion, which materially confuses what condition the metrics describe.
  - Dimension: reporting
  - Location: Introduction §1; Results §3.3–§3.4; Discussion §4
- **Limited conduct transparency** Ethics approval is declared without an identifiable board or approval number, and data are only available “upon request,” limiting verifiability.
  - Dimension: positioning
  - Location: Methods §2.1; Data Availability Statement

## Reliability checks

Concerns (4 of 4 checks).

- **Internal coherence:** Concern. Key numerical results and disease labels are internally inconsistent across the Abstract and Results, and multiple sections contain systematic terminology substitutions (e.g., "leukemia") that obscure what condition is being analyzed.
- **Research conduct:** Noted. Ethics and consent are declared, but approvals are not identifiable/verifiable from the manuscript; transparency is limited because data are only available on request and no registration or COI disclosure is provided in the supplied text.
- **Reference integrity:** Clean. All 28 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Concern
- **Summary:** This paper was retracted on 2023-10-18. See notice: 10.1155/2023/9894170.
- **Last checked:** 2026-10-17
